A detailed history of Russell Investments Group, Ltd. transactions in Bio Atla, Inc. stock. As of the latest transaction made, Russell Investments Group, Ltd. holds 192 shares of BCAB stock, worth $263. This represents 0.0% of its overall portfolio holdings.

Number of Shares
192
Holding current value
$263
% of portfolio
0.0%

Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 08, 2024

BUY
$1.88 - $3.46 $360 - $664
192 New
192 $0
Q2 2022

Jul 29, 2022

BUY
$2.13 - $5.38 $19,809 - $50,034
9,300 Added 16.26%
66,500 $189,000
Q1 2022

May 05, 2022

BUY
$4.38 - $18.78 $250,536 - $1.07 Million
57,200 New
57,200 $286,000

Others Institutions Holding BCAB

About BioAtla, Inc.


  • Ticker BCAB
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 36,304,100
  • Market Cap $49.7M
  • Description
  • BioAtla, Inc., a clinical stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its lead product candidate is BA3011, a conditionally active biologic (CAB) antibody-drug conjugate (ADC) for soft tissue and bone sarcoma tumors, non-small cell lung cancer (NSCLC), and ...
More about BCAB
Track This Portfolio

Track Russell Investments Group, Ltd. Portfolio

Follow Russell Investments Group, Ltd. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Russell Investments Group, Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Russell Investments Group, Ltd. with notifications on news.